Suppr超能文献

YUMM系:一系列具有特定基因改变的同源小鼠黑色素瘤细胞系。

The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations.

作者信息

Meeth Katrina, Wang Jake Xiao, Micevic Goran, Damsky William, Bosenberg Marcus W

机构信息

Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.

Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA.

出版信息

Pigment Cell Melanoma Res. 2016 Sep;29(5):590-7. doi: 10.1111/pcmr.12498. Epub 2016 Aug 3.

Abstract

The remarkable success of immune therapies emphasizes the need for immune-competent cancer models. Elegant genetically engineered mouse models of a variety of cancers have been established, but their effective use is limited by cost and difficulties in rapidly generating experimental data. Some mouse cancer cell lines are transplantable to immunocompetent host mice and have been utilized extensively to study cancer immunology. Here, we describe the Yale University Mouse Melanoma (YUMM) lines, a comprehensive system of mouse melanoma cell lines that are syngeneic to C57BL/6, have well-defined human-relevant driver mutations, and are genomically stable. This will be a useful tool for the study of tumor immunology and genotype-specific cancer biology.

摘要

免疫疗法的显著成功凸显了具备免疫活性的癌症模型的必要性。人们已经建立了各种优雅的基因工程小鼠癌症模型,但它们的有效应用受到成本以及快速生成实验数据的困难的限制。一些小鼠癌细胞系可移植到具有免疫活性的宿主小鼠体内,并已被广泛用于研究癌症免疫学。在此,我们描述了耶鲁大学小鼠黑色素瘤(YUMM)细胞系,这是一个全面的小鼠黑色素瘤细胞系系统,与C57BL/6同基因,具有明确的与人类相关的驱动突变,并且基因组稳定。这将成为研究肿瘤免疫学和基因型特异性癌症生物学的有用工具。

相似文献

1
The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations.
Pigment Cell Melanoma Res. 2016 Sep;29(5):590-7. doi: 10.1111/pcmr.12498. Epub 2016 Aug 3.
2
Ascophyllan functions as an adjuvant to promote anti-cancer effect by dendritic cell activation.
Oncotarget. 2016 Apr 12;7(15):19284-98. doi: 10.18632/oncotarget.8200.
3
A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model.
Int J Cancer. 2020 Mar 1;146(5):1409-1420. doi: 10.1002/ijc.32777. Epub 2019 Dec 4.
5
Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma.
J Immunol. 2012 Sep 1;189(5):2226-33. doi: 10.4049/jimmunol.1200744. Epub 2012 Jul 23.
6
EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice.
Lung Cancer. 2019 Oct;136:86-93. doi: 10.1016/j.lungcan.2019.08.019. Epub 2019 Aug 20.
7
Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors.
Oncologist. 2012;17(10):1303-16. doi: 10.1634/theoncologist.2012-0274. Epub 2012 Sep 19.
10
Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors.
Mol Cancer Ther. 2018 Apr;17(4):869-882. doi: 10.1158/1535-7163.MCT-17-1091. Epub 2018 Feb 26.

引用本文的文献

2
Targeting Cholesterol-Dependent Piezo1 Activation Impairs Amoeboid Migration in Melanoma Cells.
bioRxiv. 2025 Jul 17:2025.07.11.664494. doi: 10.1101/2025.07.11.664494.
3
A functional comparison of two transplantable syngeneic mouse models of melanoma: B16F0 and YUMM1.7.
bioRxiv. 2025 Jun 10:2025.05.09.652938. doi: 10.1101/2025.05.09.652938.
7
Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma.
J Immunother Cancer. 2025 May 15;13(5):e011551. doi: 10.1136/jitc-2025-011551.
10
NEDDylation regulates CD8+ T cell metabolism and anti-tumor immunity.
Cancer Immunol Res. 2025 Apr 22. doi: 10.1158/2326-6066.CIR-24-0127.

本文引用的文献

1
sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.
Nature. 2016 Apr 14;532(7598):250-4. doi: 10.1038/nature17392. Epub 2016 Apr 4.
2
The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
Adv Immunol. 2016;130:25-74. doi: 10.1016/bs.ai.2016.01.001. Epub 2016 Feb 10.
4
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses.
Cell. 2015 Sep 10;162(6):1217-28. doi: 10.1016/j.cell.2015.08.012. Epub 2015 Aug 27.
5
The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Matrix Biol. 2015 Oct;48:66-77. doi: 10.1016/j.matbio.2015.05.007. Epub 2015 May 16.
6
Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma.
Cancer Res. 2015 Jul 1;75(13):2619-28. doi: 10.1158/0008-5472.CAN-14-2524. Epub 2015 May 14.
7
Therapy-induced tumour secretomes promote resistance and tumour progression.
Nature. 2015 Apr 16;520(7547):368-72. doi: 10.1038/nature14336. Epub 2015 Mar 25.
8
PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.
Cancer Res. 2015 Apr 1;75(7):1399-412. doi: 10.1158/0008-5472.CAN-14-2785. Epub 2015 Feb 24.
9
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988.
10
Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032.
Pigment Cell Melanoma Res. 2014 May;27(3):495-501. doi: 10.1111/pcmr.12220. Epub 2014 Mar 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验